» Articles » PMID: 33739411

Prediagnostic Inflammation and Pancreatic Cancer Survival

Abstract

Background: Chronic inflammation may promote initiation and progression of pancreatic cancer, but no studies have examined the association between inflammation in the period before diagnosis and pancreatic cancer survival.

Methods: We prospectively examined the association of prediagnostic plasma levels of C-reactive protein, interleukin-6, and tumor necrosis factor-α receptor 2 with survival among 492 participants from 5 large US prospective cohort studies who developed pancreatic cancer. Using an empirical dietary inflammatory pattern (EDIP) score, we evaluated whether long-term proinflammatory diets were associated with survival among 1153 patients from 2 of the 5 cohorts. Cox proportional hazards regression was used to estimate hazard ratios for death with adjustment for potential confounders. All statistical tests were 2-sided.

Results: Higher prediagnostic levels of C-reactive protein, interleukin-6, and tumor necrosis factor-α receptor 2 were individually associated with reduced survival (Ptrend = .03, .01, and .04, respectively). Compared with patients with a combined inflammatory biomarker score of 0 (all 3 marker levels below medians), those with a score of 3 (all 3 marker levels above medians) had a hazard ratio for death of 1.57 (95% confidence interval = 1.16 to 2.12; Ptrend = .003), corresponding to median overall survival times of 8 vs 5 months. Patients consuming the most proinflammatory diets (EDIP quartile 4) in the prediagnostic period had a hazard ratio for death of 1.34 (95% confidence interval = 1.13 to 1.59; Ptrend = .01), compared with those consuming the least proinflammatory diets (EDIP quartile 1).

Conclusion: Prediagnostic levels of inflammatory biomarkers and long-term proinflammatory diets were inversely associated with pancreatic cancer survival.

Citing Articles

The association between empirical dietary inflammatory pattern and risk of cancer and cancer-specific mortality: a systematic review and meta-analysis of prospective cohort studies.

Hosseini F, Nikparast A, Etesami E, Javaheri-Tafti F, Asghari G Front Nutr. 2024; 11:1462931.

PMID: 39494310 PMC: 11527705. DOI: 10.3389/fnut.2024.1462931.


The Inhibitory Impact of a Co-Assembly Gel with Natural Carrier-Free Binary Small Molecules, as Used in Traditional Chinese Medicine, on the Viability of SW1990 Cells.

Nie X, Liu S, Huang Q, Wu H, Zheng Q, Xu X Gels. 2024; 10(9).

PMID: 39330171 PMC: 11431333. DOI: 10.3390/gels10090569.


Effect of smoking cessation on the likelihood of pancreatitis and pancreatic cancer.

Han X, Xu Z, Ma D, Ling Z, Dong X, Yan X Tob Induc Dis. 2024; 22.

PMID: 39006371 PMC: 11241968. DOI: 10.18332/tid/190635.


The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker.

Buyukbayram M, Hannarici Z, Duzkopru Y, Turhan A, Caglar A, Coban Esdur P Breast Cancer (Dove Med Press). 2024; 16:329-339.

PMID: 38974895 PMC: 11227876. DOI: 10.2147/BCTT.S464161.


Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women's Health Initiative.

Brasky T, Jager L, Newton A, Li X, Loomans-Kropp H, Hays J Cancer Epidemiol Biomarkers Prev. 2024; 33(9):1203-1210.

PMID: 38900510 PMC: 11371515. DOI: 10.1158/1055-9965.EPI-24-0305.


References
1.
Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M . Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter. Medicine (Baltimore). 2016; 95(18):e3582. PMC: 4863804. DOI: 10.1097/MD.0000000000003582. View

2.
Tabung F, Smith-Warner S, Chavarro J, Wu K, Fuchs C, Hu F . Development and Validation of an Empirical Dietary Inflammatory Index. J Nutr. 2016; 146(8):1560-70. PMC: 4958288. DOI: 10.3945/jn.115.228718. View

3.
Ebrahimi B, Tucker S, Li D, Abbruzzese J, Kurzrock R . Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 2004; 101(12):2727-36. DOI: 10.1002/cncr.20672. View

4.
FALCONER J, Fearon K, Ross J, Elton R, Wigmore S, Garden O . Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer. 1995; 75(8):2077-82. DOI: 10.1002/1097-0142(19950415)75:8<2077::aid-cncr2820750808>3.0.co;2-9. View

5.
Papadoniou N, Kosmas C, Gennatas K, Polyzos A, Mouratidou D, Skopelitis E . Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res. 2008; 28(1B):543-9. View